StockData

Rocket One Inc. (RKTO) stock

RKTONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.32−0.00 (-1.25%)

Close on Nov 17, 2026Market cap $7.89MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$7.89M
P/E ratio
–
Price to sales
–
Price to book
0.96
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$13.32M
EPS, diluted
-$0.83
Book value per share
$0.40
Diluted shares
21M

Trading

Previous close
$0.32
Open
$0.32
Day's range
$0.30 – $0.32
Volume
258,851
Average volume (20 days)
284,219
52-week range
$0.30 – $2.45
RSI (14 days)
19.2
Volatility (1 year)
148.9%
Relative volume
0.54×

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodRKTOS&P 500DifferenceRKTO per yearS&P 500 per year
1 month-37.5%-4.0%−33.4 pts
3 months-58.6%-5.0%−53.6 pts
Year to date-68.0%+8.2%−76.2 pts
1 year-72.9%+11.2%−84.1 pts
3 years-70.7%+68.5%−139.2 pts-33.6%+19.0%
5 years-98.6%+67.3%−165.9 pts-57.7%+10.8%

Nine years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Operating income

-$13.17M

Net income

-$13.32M

EPS, diluted

-$0.83
Reported periodTrailing twelve months

Press releases

Releases Rocket One filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Rocket One

Pharmaceutical Preparations

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new generation therapies designed to address unmet medical needs. The company's development pipeline features drug candidates targeting various conditions across oncology, dermatology, allergy, and neurology. Key pipeline assets include HT-001, a topical formulation for treating skin toxicities resulting from cancer therapies; HT-KIT, a targeted therapeutic for mast cell-derived neoplasms and anaphylaxis; and HT-ALZ, an asset aimed at treating and preventing Alzheimer’s disease and other neuroinflammatory conditions. Additional programs comprise BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity. The company creates these therapies primarily for patients requiring specialized interventions.

Company profile, executives and history

Rocket One stock: common questions

What is Rocket One's stock price?

RKTO closed at $0.32 on Nov 17, 2026, down 1.25% on the day. Over the past 52 weeks it traded between $0.30 and $2.45.

What is Rocket One's market cap?

Rocket One was worth $7.89M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is RKTO's P/E ratio?

Rocket One lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.83), so it has no meaningful P/E ratio.

Does Rocket One pay a dividend?

No. Rocket One has not paid a cash dividend over the last twelve months.

How has RKTO stock performed over the past year?

Including dividends, RKTO returned -72.9% over the past year, against +11.2% for the S&P 500.

How many RKTO shares are sold short?

1M shares were sold short at the latest FINRA report, 2.78% of the float, or 2.3 days of average trading volume.

Who are Rocket One's competitors?

Companies most similar to Rocket One by business, industry and size include RCKT, GRCE, SNGX, SNDX, HIND.

See a number that looks wrong?